Table 2.
The baseline characteristics at diagnosis of MDS patients with MF-2/3 (n = 43)
| Transplant (n = 20) | Non-transplant (n = 23) | P | |
|---|---|---|---|
| Age (years), median, range | 42 (27–60) | 58 (21–79) | 0.003 |
| Gender, no. (%) | 0.106 | ||
| Male | 10 (50.0%) | 17 (73.9%) | |
| Female | 10 (50.0%) | 6 (26.1%) | |
| Median WBC (range), × 109/L | 2.73 (1.10–12.00) | 2.91 (1.34–7.36) | 0.759 |
| Median NE (range), × 109/L | 0.85 (0.04–2.27) | 0.92 (0.16–4.92) | 0.439 |
| Median HGB (range), g/L | 65 (30–138) | 69 (36–84) | 0.706 |
| Median PLT (range), × 109/L | 41.5 (3–234) | 82 (8–282) | 0.179 |
| MDS subtypes (WHO, 2016), no. (%) | 0.290 | ||
| MDS-SLD | 2 (10.0%) | 0 (0.0%) | |
| MDS-MLD | 3 (15.0%) | 1 (4.3%) | |
| MDS-RS-SLD | 0 (0.0%) | 2 (8.7%) | |
| MDS-RS-MLD | 1 (5.0%) | 2 (8.7%) | |
| MDS with isolated 5q-deletion | 0 (0.0%) | 0 (0.0%) | |
| MDS-EB-1 | 5 (25.0%) | 5 (21.8%) | |
| MDS-EB-2 | 8 (40.0%) | 13 (56.5%) | |
| MDS-U | 1 (5.0%) | 0 (0.0%) | |
| Cytogenetic | 0.692 | ||
| Normal karyotype | 5 (25.0%) | 7 (30.4%) | |
| Aberrant karyotype | 15 (75.0%) | 16 (69.6%) | |
| IPSS-R risk group, no. (%) | 0.128 | ||
| Very low | 0 (0.0%) | 0 (0.0%) | |
| Low | 2 (10.0%) | 3 (13.0%) | |
| Intermediate | 7 (35.0%) | 2 (8.7%) | |
| High | 6 (30.0%) | 6 (26.1%) | |
| Very high | 5 (25.0%) | 12 (52.2%) | |
| Treatment, no. (%) | |||
| Cytoreductive treatments pre-transplantation | 11 (55.0%) | 0 (0.0%) | |
| Cytoreductive treatments without HSCT | 0 (0.0%) | 12 (52.2%) | |
| Immunoregulatory | 0 (0.0%) | 5 (21.7%) | |
| Supportive care | 0 (0.0%) | 6 (26.1%) | |
| Leukemia transformation, no. (%) | 6 (30.0%) | 2 (8.3%) | 0.115 |
| Median time from diagnosis to leukemia transformation, months (range) | 7 (1–20) | 12 (9–15) | 0.249 |